Literature DB >> 5318612

Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon.

A M Connell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5318612      PMCID： PMC1846334          DOI： 10.1136/bmj.2.5466.848

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  6 in total

1.  PHARMACOLOGICAL PROPERTIES OF MEBEVERINE, A SMOOTH-MUSCLE RELAXANT.

Authors:  A LINDNER; H SELZER; V CLAASSEN; P GANS; O R OFFRINGA; J M ZWAGEMAKERS
Journal:  Arch Int Pharmacodyn Ther       Date:  1963-10-01

2.  OBSERVATIONS ON THE CLINICAL USE OF RADIO PILLS.

Authors:  A M CONNELL; J MCCALL; J J MISIEWICZ; E N ROWLANDS
Journal:  Br Med J       Date:  1963-09-28

3.  Wireless telemetering from the digestive tract.

Authors:  A M CONNELL; E N ROWLANDS
Journal:  Gut       Date:  1960-09       Impact factor: 23.059

4.  The motility of the pelvic colon. 1. Motility in normals and in patients with asymptomatic duodenal ulcer.

Authors:  A M CONNELL
Journal:  Gut       Date:  1961-06       Impact factor: 23.059

5.  Reserpine analogues.

Authors:  T KRALT; H D MOED; V CLAASSEN; T W HENDRIKSEN; A LINDNER; H SELZER; F BRUECKE; G HERTTING; G GOGOLAK
Journal:  Nature       Date:  1960-12-24       Impact factor: 49.962

6.  Effects of certain antispasmodic drugs on the intact human colon, with special reference to banthine (beta-diethylaminoethyl xanthene-9-carboxylate methobromide).

Authors:  F KERN; T P ALMY; N J STOLK
Journal:  Am J Med       Date:  1951-07       Impact factor: 4.965
  6 in total
  11 in total

1.  The irritable colon syndrome.

Authors:  A M Connell
Journal:  Postgrad Med J       Date:  1968-09       Impact factor: 2.401

Review 2.  A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.

Authors:  Mahnaz Darvish-Damavandi; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

3.  A double-blind randomised, placebo-controlled trial evaluating the influence of oral long-acting muscle relaxant (Mebeverine MR), and insufflation with CO(2) on pain associated with barium enema.

Authors:  A S Lowe; A H Chapman; D Wilson; A G Culpan
Journal:  Eur Radiol       Date:  2003-01-14       Impact factor: 5.315

4.  Comparison of various treatments for irritable bowel syndrome.

Authors:  J A Ritchie; S C Truelove
Journal:  Br Med J       Date:  1980-11-15

Review 5.  Evaluation of drug treatment in irritable bowel syndrome.

Authors:  Nicholas J Talley
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 6.  The irritable bowel syndrome.

Authors:  S M Collins
Journal:  CMAJ       Date:  1988-02-15       Impact factor: 8.262

Review 7.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

8.  Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study.

Authors:  Ramesh R Rai; Sandeep Nijhawan
Journal:  Saudi J Gastroenterol       Date:  2021 May-Jun       Impact factor: 2.485

9.  Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

Authors:  Dwaipayan Sarathi Chakraborty; Avijit Hazra; Amrita Sil; Shantasil Pain
Journal:  J Family Med Prim Care       Date:  2019-10-31

Review 10.  Pharmacologic Agents for Chronic Diarrhea.

Authors:  Kwang Jae Lee
Journal:  Intest Res       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.